Releases and Announcements

Duane Morris Named Top 5 Global Legal Advisor in Biotech and Pharma Licensing Deals

August 29, 2013

SAN DIEGO, August 29, 2013—Duane Morris LLP is pleased to announce that it has been named one of the top legal advisors worldwide in biotech and pharma licensing deals, according to BioPharm Insight, an independent business intelligence firm that is part of the Financial Times Group.

According to BioPharm Insight's second quarter league tables, Duane Morris tied for 5th place by number of global licensing deals,and ranked in 8th place by deal value. The rankings represent the growth of Duane Morris' Life Sciences Group, which recently added two new partners to its practice. Jonathan Lourie joined the firm's Boston office in July, and Les Croland joined the firm's Miami office in March, adding to Duane Morris' already robust capabilities in representing clients in the life sciences. The rankings also highlight the strength of the firm's Technology Transactions & Licensing practice group, which assists clients with licensing and collaboration transactions.

Attorneys in the firm's Life Sciences group represent life sciences entities with a broad range of technologies in all stages of development, from startups seeking initial capital investment to multinational, publicly traded companies, including pharmaceutical companies, biotech companies, medical device manufacturers, academic research institutions, university technology transfer offices and clinical laboratories. Many of the firm's life sciences attorneys have served as in-house counsel at pharma and biotech companies; earned Ph.D.s in biology, biochemistry and/or molecular and developmental genetics; have worked at FDA consulting firms; or were scientists in research laboratories in cancer and genetics.

About Duane Morris

Duane Morris LLP, a law firm with more than 700 attorneys in offices across the Unites States and internationally, is asked by a broad array of clients to provide innovative solutions to today's legal and business challenges.